Trem‐cel, an allogeneic gene‐edited product matched to HLAs, could treat AML patients at high risk of leukemic relapse and posttransplant mortality, with the promise of mitigating the hematologic toxicity associated with anti‐CD33 cell therapy. Here, CD33 is linked to acute myeloid leukemia.